Evidence map›Paper›PMID 23182741›Full record

ArticleFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association2013

Inhibition of herpes simplex virus type 1 with the modified green tea polyphenol palmitoyl-epigallocatechin gallate.

Aline de Oliveira, Sandra D Adams, Lee H Lee, Sean R Murray, Stephen D Hsu, Jeffrey R Hammond, Douglas Dickinson, Ping Chen, Tin-Chun Chu

Abstract read
In one paragraph

Article in Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 80 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Anti-HSV-1 agents: an update.Frontiers in pharmacology · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Effects of Epigallocatechin-3-Gallate-Palmitate (EC16) onMicrobiology & infectious diseases (Wilmington, Del.) · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Aline de OliveiraDepartment of Biological Science, Seton Hall University, South Orange, NJ 07079, USA.
Sandra D Adams
Lee H Lee
Sean R Murray
Stephen D Hsu
Jeffrey R Hammond
Douglas Dickinson
Ping Chen
Tin-Chun Chu
California State University, Northridge · USMontclair State University · USSeton Hall University · USAugusta University · USZhejiang University · CN

Funding

Integrating lipid biosynthesis with bacterial cell cycle progressionSC2GM084860 · NIGMS · CALIFORNIA STATE UNIVERSITY NORTHRIDGE · PI MURRAY, SEAN · 2008 to 2010
$391k
NIGMS NIH HHS GM084860NIGMS NIH HHS SC2 GM084860
6 · The paper itself

Abstract

Green tea polyphenol epigallocatechin gallate (EGCG) is a strong antioxidant that has previously been shown to reduce the number of plaques in HIV-infected cultured cells. Modified EGCG, palmitoyl-EGCG (p-EGCG), is of interest as a topical antiviral agent for herpes simplex virus (HSV-1) infections. This study evaluated the effect of p-EGCG on HSV-infected Vero cells. Results of cell viability and cell proliferation assays indicate that p-EGCG is not toxic to cultured Vero cells and show that modification of the green tea polyphenol epigallocatechin gallate (EGCG) with palmitate increases the effectiveness of EGCG as an antiviral agent. Furthermore, p-EGCG is a more potent inhibitor of herpes simplex virus 1 (HSV-1) than EGCG and can be topically applied to skin, one of the primary tissues infected by HSV. Viral binding assay, plaque forming assay, PCR, real-time PCR, and fluorescence microscopy were used to demonstrate that p-EGCG concentrations of 50 μM and higher block the production of infectious HSV-1 particles. p-EGCG was found to inhibit HSV-1 adsorption to Vero cells. Thus, p-EGCG may provide a novel treatment for HSV-1 infections.

Indexed as

AnimalsAntigens, ViralAntiviral AgentsCatechinCell ProliferationCell SurvivalChlorocebus aethiopsDose-Response Relationship, DrugGene Expression Regulation, ViralGreen Fluorescent ProteinsHerpes SimplexHerpesvirus 1, HumanMicroscopy, FluorescenceTeaVero CellsViral Envelope ProteinsAntigens, ViralAntiviral AgentsCatechinepigallocatechin gallateglycoprotein D, Human herpesvirus 1Green Fluorescent ProteinsTeaUL46 protein, Human herpesvirus 1Viral Envelope ProteinsViral Proteins

Identifiers

PMID23182741
PMCPMC3703635
OpenAlexW2024678649

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.